Influence of repeated oral doses of ethinyloestradiol on the metabolic disposition of [C-13(2)]-ethinyloestradiol in young women

被引:8
作者
Kuhnz, W
Humpel, M
Biere, H
Gross, D
机构
[1] Research Laboratories, Schering AG
关键词
ethinyloestradiol; clearance; stable isotope;
D O I
10.1007/s002280050098
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: To examine the influence of daily oral administration of ethinyloestradiol on the total clearance of C-13-labeled ethinyloestradiol in women. Methods: 19, healthy young women received a single IV dose of 0.06 mg C-ethinyloestradiol. Subsequently, they were treated with daily oral doses of 0.06 mg ethinyloestradiol for 8 days. On the last day of oral treatment, they received a further IV dose of 0.06 mg C-13-ethinyloestradiol. The pharmacokinetic parameters clearance, area under the serum level-time curve, terminal half-life, steady-state volume of distribution and mean residence time of C-13-ethinyloestradiol in each volunteer were evaluated after both IV doses, and the corresponding pairs of parameters were examined statistically for the significance of intraindividual differences. Results: Following the first (second) intravenous administration, the mean area under the curve was 2.54 (2.67) ng . h . ml(-1). The terminal half-life and mean residence time were 9.7 (9.6)h and 10.5 (10.1) h, respectively. The steady-state volume of distribution was 4.3 (3.9) 1 . kg(-1) and the clearance was 7.0 (6.6) ml . min(-1) . kg(-1). No significant difference was observed in any of these parameters between the first and the second TV doses of C-13-EE(2). Conclusions: Since the clearance in particular remained unchanged after repeated oral administration of ethinyloetradiol, the hypothesis that ethinyloestradiol can inhibit its own metabolism in vivo can be rejected.
引用
收藏
页码:231 / 235
页数:5
相关论文
共 15 条
[1]  
ABDELAZIZ MT, 1970, STEROIDS, V15, P695
[2]   ASSAY OF ETHYNYLOESTRADIOL IN HUMAN-SERUM AND ITS BINDING TO PLASMA-PROTEINS [J].
AKPOVIRORO, J ;
FOTHERBY, K .
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1980, 13 (07) :773-779
[3]   COMPARATIVE PHARMACOKINETICS OF LEVONORGESTREL AND ETHINYLESTRADIOL FOLLOWING INTRAVENOUS, ORAL AND VAGINAL ADMINISTRATION [J].
BACK, DJ ;
GRIMMER, SFM ;
ROGERS, S ;
STEVENSON, PJ ;
ORME, MLB .
CONTRACEPTION, 1987, 36 (04) :471-479
[4]  
BOCKER R, 1991, CONTRACEPTION, V7, P140
[5]   GROUP COMPARISON OF SERUM ETHINYL ESTRADIOL, SHBG AND CBG LEVELS IN 83 WOMEN USING 2 LOW-DOSE COMBINATION ORAL-CONTRACEPTIVES FOR 3 MONTHS [J].
DIBBELT, L ;
KNUPPEN, R ;
JUTTING, G ;
HEIMANN, S ;
KLIPPING, CO ;
PARIKKAOLEXIK, H .
CONTRACEPTION, 1991, 43 (01) :1-21
[6]   PHARMACOKINETICS OF ETHINYL ESTRADIOL AND MESTRANOL [J].
GOLDZIEHER, JW ;
BRODY, SA .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1990, 163 (06) :2114-2119
[7]   INTERACTION WITH THE PHARMACOKINETICS OF ETHINYLESTRADIOL AND PROGESTOGENS CONTAINED IN ORAL-CONTRACEPTIVES [J].
JUNGHOFFMANN, C ;
KUHL, H .
CONTRACEPTION, 1989, 40 (03) :299-312
[8]   PLASMA-LEVELS OF ETHINYLESTRADIOL (EE) DURING CYCLIC TREATMENT WITH COMBINED ORAL-CONTRACEPTIVES [J].
KAUFMAN, JM ;
THIERY, M ;
VERMEULEN, A .
CONTRACEPTION, 1981, 24 (05) :589-602
[9]  
KRAAN GPB, 1988, APPL RADIAT ISOTOPES, V39, P594
[10]   CONCENTRATION OF ETHINYL ESTRADIOL IN THE SERUM OF 31 YOUNG-WOMEN FOLLOWING A TREATMENT PERIOD OF 3 MONTHS WITH 2 LOW-DOSE ORAL-CONTRACEPTIVES IN AN INTRAINDIVIDUAL CROSS-OVER DESIGN [J].
KUHNZ, W ;
BACK, D ;
POWER, J ;
SCHUTT, B ;
LOUTON, T .
HORMONE RESEARCH, 1991, 36 (1-2) :63-69